-- 据周二提交给澳大利亚证券交易所的文件显示，Starpharma Holdings（ASX：SPL）已收到美国食品药品监督管理局（FDA）对其DEP HER2放射疗法候选药物首次人体I期临床试验方案的积极反馈。 该公司正在开发该候选药物，用于治疗某些胃癌/胃食管交界处癌以及其他既往接受过靶向治疗的晚期癌症患者。 美国FDA的反馈支持启动I期临床试验的计划，该试验预计将于今年下半年开始。 Starpharma表示，FDA还确认该放射疗法候选药物针对的人群存在显著的未满足医疗需求，这表明该药物有可能获得快速通道资格或其他加速开发途径。 该公司股价在周二的交易中上涨了7%。
Related Articles
Asia
Hong Kong Stocks Edge Lower as U.S.-Iran Talks Stall; CITIC Securities Gains on Profit Jump
Hong Kong stocks ended little changed Monday as U.S.-Iran talks stalled, heightening concerns over potential disruptions to energy flows.The Hang Seng Index fell 52.42 points to end marginally lower at 25,925.65, while the Hang Seng China Enterprises Index dropped 19.30 points to 8,756.32.U.S. President Donald Trump scrapped plans to send envoys to Islamabad for weekend talks, signaling a pause in diplomatic efforts.He said Sunday Iran could call if it wants to negotiate an end to the conflict, while insisting it must not possess nuclear weapons, after Tehran urged the removal of obstacles to a deal, including the U.S. blockade of its ports.Sentiment was partially supported after an Axios report said Iran may prioritize reopening the strait while postponing nuclear negotiations.Meanwhile, China's industrial profits accelerated in March, marking their fastest growth in six months.Profits rose 15.8% year on year, up from a 15.2% increase in the January-February period, according to data from the National Bureau of Statistics released Monday.In corporate news, CITIC Securities (HKG:6030, SHA:600030) closed nearly 2% higher after reporting a 55% growth in first-quarter profit.
$^HSI$HKG:6030$SHA:600030
Asia
WuXi AppTec's Q1 Profit Up 27%
WuXi AppTec (HKG:2359) booked 4.65 billion yuan in attributable profit for the first quarter of 2026, up 27% from 3.67 billion yuan a year earlier, according to a Hong Kong bourse filing Monday.Earnings per share were 1.58 yuan, compared with 1.28 yuan in the prior year.Revenue jumped 29% year on year to 12.44 billion yuan, figures showed.
$HKG:2359
Asia
Care Health Insurance CEO Steps Down
Religare Enterprises (NSE:RELIGARE, BOM:532915) said the managing director and chief executive officer of its subsidiary, Care Health Insurance, has stepped down from the role on April 25 upon completion of tenure, according to an Indian bourse filing on Sunday.Shares of the company rose nearly 2% in Monday's trade.
$BOM:532915$NSE:RELIGARE